Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Graphene Sensors May Help to Detect Sepsis Earlier in Critically Ill Patients

A new study from the University of Bath has shown that graphene-based biosensors, designed by Integrated Graphene, have the potential to play a major role in detecting increased levels of lactate, an important biomarker for the treatment of critically ill patients.

The research, published in Sensor and Actuators: B.Chemical1, shows that Integrated Graphene’s Gii-Sens™ electrochemical sensor can improve accuracy in the diagnosis of hyperlactatemia, a common complication in intensive care units.

Hyperlactatemia results from a lack of oxygen reaching tissues or as a result of an underlying condition, such as advanced liver disease. Untreated hyperlactatemia can lead to lactate acidosis, which causes severe illness and can be fatal. Reliable real-time lactate detection through single-point or continuous monitoring could help to improve the outcomes of patients in critical care and could hasten the diagnosis of sepsis in critically ill patients.

Based in Stirling, Integrated Graphene’s flagship product, Gii-Sens™ is a biosensing electrode for diagnostics which outperforms traditional sensing materials by 10-100 times, allowing for cost effective, lab precision testing within minutes at the point of need. Other applications of the technology include quality control in the food production industry, and wearable lactate sensors which can be used to monitor an athlete’s performance in real time.

Dr Marco Caffio, Integrated Graphene’s Co-Founder and CSO, said: “Lactate is a naturally occurring biomarker which everyone produces as a byproduct of exercising. For most people it is easily processed by the body and will cause no major harm, apart from a little cramp if you overexert yourself.

“However, for some critically ill patients and those with underlying conditions it can be a sign of a range of other issues, some of which, like sepsis, can be fatal. Having a robust way of monitoring lactate levels is important in ensuring the best possible outcomes for these patients. The findings of this study demonstrate Gii’s reliable performance and potential to save lives.”

 

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy